Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

731
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
731
Dementia01:30

Dementia

476
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
476
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

916
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
916
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

492
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
492
Drug Therapy01:28

Drug Therapy

225
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subtyping and staging of Alzheimer's disease from routine structural MRI with PHASE-AD.

medRxiv : the preprint server for health sciences·2026
Same author

The DECISION Study: Protocol for the Development and Internal Validation of a Multimodal Decision-Making Capacity Framework.

Journal of clinical epidemiology·2026
Same author

Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.

Nature communications·2026
Same author

Obstacles and solutions for implementing amyloid-targeting treatments in Europe.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer's disease.

Aging clinical and experimental research·2026
Same author

Estimation of positron emission tomography amyloid load and related biomarkers in Alzheimer's disease using evoked potential tomography EEG: development and internal validation in a cross-sectional cohort.

Alzheimer's research & therapy·2026

Related Experiment Video

Updated: Jan 5, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.7K

Dementia treatment versus prevention.

Robert Perneczky1

  • 1Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Neuroepidemiology and Ageing Research Unit, School of Public Health, Imperial College London, London, UK.

Dialogues in Clinical Neuroscience
|October 15, 2019
PubMed
Summary

Alzheimer disease (AD) treatments currently offer only symptomatic relief. Research focuses on amyloid-beta clearance, but drug development has failed, necessitating exploration of non-pharmacological prevention strategies for dementia risk.

Keywords:
Alzheimer diseasebiomarkerclinical trialdementiaepidemiologymild cognitive impairmentpreventionprognosispublic healthtreatment

More Related Videos

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.1K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

Related Experiment Videos

Last Updated: Jan 5, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

33.7K
Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.1K
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.9K

Area of Science:

  • Neuroscience
  • Gerontology
  • Pharmacology

Background:

  • Alzheimer disease (AD) and dementia prevalence are rising globally due to aging populations.
  • Current treatments for AD, such as acetylcholinesterase inhibitors and memantine, provide only symptomatic relief.
  • No disease-modifying drugs are currently available for AD.

Purpose of the Study:

  • To review the current landscape of Alzheimer disease (AD) treatment and prevention strategies.
  • To highlight the challenges and failures in developing disease-modifying drugs targeting amyloid-beta (Aβ) clearance.
  • To discuss the role and challenges of non-pharmacological prevention trials for dementia risk.

Main Methods:

  • Review of current pharmacological treatments for Alzheimer disease (AD).
  • Analysis of research on the amyloid cascade hypothesis and drug development targeting amyloid-beta (Aβ) clearance.
  • Evaluation of non-pharmacological prevention trials for dementia risk factors.

Main Results:

  • Existing AD treatments offer symptomatic benefits but lack disease-modifying properties.
  • Drug development efforts targeting amyloid-beta (Aβ) clearance have consistently failed to yield effective therapies.
  • Non-pharmacological prevention trials show promise but require independent cohort replication.

Conclusions:

  • There is a critical unmet need for disease-modifying treatments for Alzheimer disease (AD).
  • Targeting amyloid-beta (Aβ) clearance has been a primary focus for drug development, but success has been elusive.
  • Non-pharmacological interventions represent a complementary approach to managing dementia risk, though further validation is needed.